Inactive Instrument

Press Releases Nemus Bioscience Inc OTC Bulletin Board

Equities

Press Releases

Unlock all the news: Be the first to know and act before the market!

Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting	05-13	AQ
Skye Bioscience Uplists to The Nasdaq Global Market	04-10	AQ
SKYE BIOSCIENCE : AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS - Form 8-K	04-03	PU
Skye Bioscience Announces $40 Million Private Placement Equity Financing	03-11	NE
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors	03-04	AQ
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension	02-26	AQ
Skye Bioscience to Present at Oppenheimer Investor Conference	02-07	NE
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing	01-29	NE
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease	01-09	NE
Skye Bioscience Responds to OTC Markets Promotional Policy	12-11	AQ
Skye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab	12-11	AQ
Skye Bioscience Responds to OTC Markets Promotional Policy	12-08	NE
Ocular Hypertension Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 \| Nicox, Qlaris Bio, TheratOcular Biotek Co., Ltd., Ocular Therapeutix, Whitecap Biosciences, and others.	12-06	AQ
Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa	12-05	NE
Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion	11-28	AQ
Skye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit	11-21	NE
Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma	25/10/23	NE
CORRECTION, Skye Bioscience to Host Virtual Investor Day on October 25, 2023, 'CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System'	23/10/23	AQ
Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"	20/10/23	NE
Skye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a Trial	27/09/23	NE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Nemus Bioscience Inc OTC Bulletin Board

Equities

Press Releases

Filters